RxDoctor Payments Data

Jose Burbano de Lara, MD

Family Medicine · Carrollton, TXNPI 1689604647

Payments from drug & device makers

$56,568in general payments, 2019–2025

Across 694 payments — averaging $81.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$30K
  • AstraZeneca$13K
  • Sanofi US Services Inc.$3K
  • AbbVie$2K
  • Novo Nordisk$2K
  • Amgen$1K
  • plus $6K from 48 others

What the payments were for

  • Food & beverage$9,77385%
  • Education$3153%
  • Gifts$1,31411%
  • Other$550%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,568 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$94,077
Medicare patients
355
Services billed
1,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide162$238,418
JardianceEmpagliflozin135$171,912
EliquisApixaban111$141,806
MounjaroTirzepatide109$140,816
FarxigaDapagliflozin Propanediol72$79,457
LinzessLinaclotide48$41,809
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$34,920
RybelsusSemaglutide27$34,267
MyrbetriqMirabegron39$30,162
Tresiba Flextouch U-200Insulin Degludec28$28,041
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog29$27,969
VascepaIcosapent Ethyl28$25,151
TrulicityDulaglutide20$23,098
JanuviaSitagliptin Phosphate16$23,025
Tresiba Flextouch U-100Insulin Degludec33$21,925

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$1,799$276,634205 claims
Boehringer IngelheimJardiance$513$171,912135 claims
Lilly USA, LLCMounjaro, Trulicity$323$163,914129 claims
PfizerEliquis$472$141,806111 claims
AstraZenecaFarxiga, Symbicort$12,627$85,54588 claims
GSKTrelegy Ellipta, Breo Ellipta$467$52,46582 claims
AbbVieLinzess, Synthroid$2,480$46,58992 claims
Astellas Pharma US IncMyrbetriq$237$30,16239 claims
MerckJanuvia$226$23,02516 claims
Sumitomo Pharma America, Inc.Gemtesa$68$15,73421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Carrollton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →